Rophylac Advertising Letter (correction)
This article was originally published in The Pink Sheet Daily
Executive Summary
ZLB Behring received an "untitled" letter from the Center for Biologics Evaluation & Research dated Feb. 3 regarding promotional practices of its IGIV product Rophylac. In a Feb. 7 1article, "The Pink Sheet" DAILY inadvertently categorized it as a "warning" letter